DRUG MANUFACTURER-DISCLOSURES House SponsorsRep. Mary E. Flowers-Michael J. Zalewski-LaToya Greenwood-Rita Mayfield and Elizabeth Hernandez 1/13/2021HouseSession Sine Die 410 ILCS 620/16.2 new410 ILCS 620/16.3 new Amends the Illinois Food, Drug and Cosmetic Act. Requires manufacturers of brand name or generic prescription drugs to notify State purchasers, health insurers, health care service plan providers, pharmacy benefit managers, and the General Assembly of specified increases in drug prices at least 60 days before such increase and the cost of specified new prescription drugs within 3 days after approval by the U.S. Food and Drug Administration. Provides that within 30 days after such notifications, prescription drug manufacturers shall report specified information to State purchasers, health insurers, health care service plan providers, pharmacy benefit managers, and the General Assembly. Provides that failure to report such information shall result in a specified civil penalty. Requires the General Assembly to conduct an annual public hearing on aggregate trends in prescription drug pricing. Provides that if the manufacturer of a prescription drug or its agent meets or otherwise communicates with a prescriber for the purpose of marketing a drug, then the manufacturer or its agent shall disclose to the prescriber if any ingredient in the drug it is marketing is known to pose a risk of dependency in humans. Makes other changes. 12/7/2018HousePrefiled with Clerk by Rep. Mary E. Flowers 1/9/2019HouseFirst Reading 1/9/2019HouseReferred to Rules Committee 1/29/2019HouseAssigned to Prescription Drug Affordability & Accessibility Committee 2/14/2019HouseAdded Chief Co-Sponsor Rep. Michael J. Zalewski 2/27/2019HouseAdded Chief Co-Sponsor Rep. LaToya Greenwood 2/27/2019HouseAdded Chief Co-Sponsor Rep. Rita Mayfield 3/13/2019HouseAdded Co-Sponsor Rep. Elizabeth Hernandez 3/21/2019HouseHouse Committee Amendment No. 1 Filed with Clerk by Rep. Mary E. Flowers 3/21/2019HouseHouse Committee Amendment No. 1 Referred to Rules Committee 3/26/2019HouseHouse Committee Amendment No. 1 Rules Refers to Prescription Drug Affordability & Accessibility Committee 3/29/2019HouseRule 19(a) / Re-referred to Rules Committee 3/29/2019HouseHouse Committee Amendment No. 1 Rule 19(c) / Re-referred to Rules Committee 1/13/2021HouseSession Sine Die